William John Sibold sold $1.4M of MDGL
President and CEO at MADRIGAL PHARMACEUTICALS, INC.. 2,500 shares at an average of $547.30, traded Jul 20, 2026, filed Jul 20, 2026.
Score components
- +25RoleCEO
- +25Trade size$1.4M at market
- 0Share of holdings soldSold 1.2% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-048919, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | MOption exercise Common Stock | +50,000 | - | - | 211,829 | Jul 20, 2026 |
| Jul 20, 2026 | SOpen-market sale Common Stock | -140 | $542.75 | $76k | 211,689 | Jul 20, 2026 |
| Jul 20, 2026 | SOpen-market sale Common Stock | -110 | $543.79 | $60k | 211,579 | Jul 20, 2026 |
| Jul 20, 2026 | SOpen-market sale Common Stock | -545 | $544.71 | $297k | 211,034 | Jul 20, 2026 |
| Jul 20, 2026 | SOpen-market sale Common Stock | -275 | $545.71 | $150k | 210,759 | Jul 20, 2026 |
| Jul 20, 2026 | SOpen-market sale Common Stock | -269 | $547.08 | $147k | 210,490 | Jul 20, 2026 |
| Jul 20, 2026 | SOpen-market sale Common Stock | -680 | $547.70 | $372k | 209,810 | Jul 20, 2026 |
| Jul 20, 2026 | SOpen-market sale Common Stock | -47 | $548.87 | $26k | 209,763 | Jul 20, 2026 |
| Jul 20, 2026 | SOpen-market sale Common Stock | -153 | $550.01 | $84k | 209,610 | Jul 20, 2026 |
| Jul 20, 2026 | SOpen-market sale Common Stock | -1 | $550.72 | $551 | 209,609 | Jul 20, 2026 |
| Jul 20, 2026 | SOpen-market sale Common Stock | -280 | $555.05 | $155k | 209,329 | Jul 20, 2026 |
| Jul 17, 2026 | MOption exercise Performance Restricted Stock Unitsderivative | -50,000 | $0.00 | $0 | 0 | Jul 20, 2026 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 30Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $342k 664 shares | -5% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $517k 1,042 shares | -9% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Richard S Levy director | $2.9M 5,682 shares | -21% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $435k 844 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub Pres., R&D, and CMO | $212k 491 shares | -0% | |
| 61Notable | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $718k 1,663 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.